公开(公告)号：US20240398736A1

公开(公告)日：2024-12-05

申请号：US18266103

申请日：2021-09-01

Applicant: Tsubota Laboratory, Inc. ,  ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Kazuo Tsubota ,  Toshihide Kurihara ,  Shinichi Ikeda ,  Kiwako Mori ,  Xiaoyan Jiang

IPC: A61K31/192 ,  A61P27/10 ,  G01N33/50

Abstract: The present invention provides a screening method for searching a component inhibiting or treating scleral thinning, and eyedrops that contain the active ingredient, and hence can inhibit excessive thinning of the sclera, and as a result, can treat a posterior segment eye disease associated with the scleral thinning. The problems are solved by eyedrops containing, as an active ingredient, a component capable of simultaneously inhibiting the PERK pathway and/or the ATF6 pathway. The problems are solved by a screening method for a component capable of simultaneously inhibiting the PERK pathway and/or the ATF6 pathway, including a step of contacting a candidate substance with an eye-derived cell, and a step of selecting the candidate substance using, as an indicator, influence on scleral thinning in the cell.

公开(公告)号：US20240255781A1

公开(公告)日：2024-08-01

申请号：US18564751

申请日：2022-05-27

Applicant: JINS HOLDINGS Inc. ,  Tsubota Laboratory, Inc.

Inventor： Daisuke KANEDA

IPC: G02C11/00 ,  G02C5/14

CPC classification number: G02C11/00 ,  G02C5/14

Abstract: Eyewear includes a front, a pair of end pieces disposed at both ends of the front, a pair of temples respectively connected to the pair of end pieces, and a cartridge having a raw material containing portion that contains a raw material, a spray element that uses the raw material to spray a mist, and a control circuit substrate that controls the spray element, and the cartridge is detachably connected to the temple or the end piece.

公开(公告)号：US20230338307A1

公开(公告)日：2023-10-26

申请号：US18246508

申请日：2021-09-24

Applicant: TSUBOTA LABORATORY, INC.

Inventor： Emi NISHIMURA

IPC: A61K31/12 ,  A61K9/00 ,  A61P27/04

CPC classification number: A61K31/12 ,  A61K9/0048 ,  A61P27/04

Abstract: The present disclosure pertains to provision of: a tear layer stabilizer; a prophylactic agent, ameliorating agent, and therapeutic agent for corneal epithelial disorders; a prophylactic agent, ameliorating agent, and therapeutic agent for meibomian gland dysfunction; and a prophylactic agent, ameliorating agent, and therapeutic agent for dry eye. More specifically, provided are a tear layer stabilizer, a prophylactic agent, ameliorating agent, and therapeutic agent for corneal epithelial disorders, and a prophylactic agent, ameliorating agent, and therapeutic agent for meibomian gland dysfunction, and a prophylactic agent, ameliorating agent, and therapeutic agent for dry eye, each of which composition contains apocynin as an active ingredient.

公开(公告)号：US20210308481A1

公开(公告)日：2021-10-07

申请号：US17264176

申请日：2019-08-01

Applicant: TSUBOTA LABORATORY, INC. ,  SUMITOMO DAINIPPON PHARMA CO., LTD.

Inventor： Motoshi HAYANO ,  Kazuo TSUBOTA

IPC: A61N5/06

Abstract: To provide a brain wave and cell activity control device and method based on light stimulation in which light having a specific wavelength, such as violet light, is irradiated using continuous light or a specific blinking frequency, and a device for improvement, prevention, or increase in brain function. The above-described problem is solved by a brain wave and cell activity control device, based on light stimulation, that controls brain waves or cell activity by irradiating light having a specific wavelength onto a subject using continuous light or a specific blinking frequency. The brain wave and cell activity control device comprises a light source that irradiates the light having a specific wavelength using continuous light or a specific blinking frequency, and a control unit that controls an emission of light that induces specific brain waves, the brain waves of the subject having received the light being the same or substantially the same as, or different from a frequency of the light in an irradiation state. At this time, the light is preferably violet light, and the irradiation state of the light is preferably continuous light or a blinking frequency greater than 0 Hz and less than or equal to 150 Hz.

公开(公告)号：US20200150457A1

公开(公告)日：2020-05-14

申请号：US16561776

申请日：2019-09-05

Applicant: TSUBOTA LABORATORY, INC.

Inventor： Shinichi IKEDA ,  Xiaoyan JIANG ,  Kazuo TSUBOTA ,  Toshihide KURIHARA

IPC: G02C7/06 ,  A01K67/02 ,  A61K31/575 ,  A61K9/00

Abstract: A model that closely resembles human excessive myopia can be prepared by mounting a minus lens (2) and a protector (4) to a juvenile mouse, the minus lens having an angle and a width adjustable in response to growth of the mouse. Further, this model analysis shows that myopia induction causes endoplasmic reticulum stress in a sclera and the endoplasmic reticulum stress induces myopia. Furthermore, it is revealed that an endoplasmic reticulum stress suppressant, particularly, phenylbutyrate and tauroursodeoxycholic acid act as a myopia prevention/suppression agent.

公开(公告)号：USD1067314S1

公开(公告)日：2025-03-18

申请号：US29761621

申请日：2020-12-10

Applicant: JINS HOLDINGS Inc. ,  TSUBOTA LABORATORY, Inc.

Designer： Daisuke Kaneda

公开(公告)号：US20240033311A1

公开(公告)日：2024-02-01

申请号：US18483161

申请日：2023-10-09

Applicant: TSUBOTA LABORATORY, INC. ,  ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Kazuo TSUBOTA ,  Toshihide KURIHARA

IPC: A61K36/16 ,  A61P27/10 ,  A61K9/00 ,  A61K31/05 ,  A61K31/202

CPC classification number: A61K36/16 ,  A61P27/10 ,  A61K9/0056 ,  A61K31/05 ,  A61K31/202

Abstract: The ophthalmic composition effective for the prevention or treatment of myopia or ocular diseases are provided. In particular, the present invention provides an ophthalmic composition effective in a growing child or a young person in whom myopia develops and progresses, as well as a middle-aged and elderly person in whom age-related ocular diseases such as cataract, glaucoma, retinal detachment, retinopathy, maculopathy, choroidal neovascularization, posterior staphyloma, and optic neuropathy develop, a functional food containing the ophthalmic composition, and a screening method capable of searching for the same. [Solution] The above problem is solved by an ophthalmic composition or functional food product containing at least one component selected from the group consisting of crocetin and its pharmaceutically acceptable salts and ginkgo leaf extract.

公开(公告)号：US20230218164A1

公开(公告)日：2023-07-13

申请号：US18000601

申请日：2022-03-10

Applicant: TSUBOTA LABORATORY, INC.

Inventor： Kazuo TSUBOTA ,  Hidenaga KOBASHI ,  Naoko KATO

IPC: A61B3/107 ,  A61B3/14

CPC classification number: A61B3/107 ,  A61B3/14 ,  A61B2560/06

Abstract: A simple diagnosis assisting device (10) for keratoconus and/or astigmatism, including a mobile terminal (10A) including a camera (2) and a transceiver function (3), and integrally or separately provided with a light source (1) for simultaneously projecting ring light onto both eyes. The light source (1) emits the ring light upon being attached to the mobile terminal (10A) in a case of being separately provided to the mobile terminal (10A), and emits the ring light from the mobile terminal (10A) in a case of being integrally provided to the mobile terminal (10A). The camera (2) simultaneously captures a projected image of both eyes onto which the ring light is projected. The ring light may be multiplex ring light or simplex ring light, and is configured in a ring shape by a plurality of point light sources or is configured in a ring shape by a single linear light source.

公开(公告)号：US20200092971A1

公开(公告)日：2020-03-19

申请号：US16473487

申请日：2017-12-26

Applicant: TSUBOTA LABORATORY, INC.

Inventor： Kazuo TSUBOTA

IPC: H05B37/02 ,  G06F3/147

Abstract: To provide a display system such as a smartphone, a game console, a personal computer, or a liquid crystal television, including a light-emitting element that irradiates light having a specific wavelength toward a user. The above-described problem is solved by a display system (1) including a first light-emitting element (6) that emits light used for image display, a second light-emitting element (3) that irradiates light (7) within a wavelength range of 360 nm to 400 nm, inclusive, toward a user, and a control unit (10) that controls irradiation of the light (7) from the second light-emitting element (3). At this time, the second light-emitting element (3) may be a single light-emitting element integrated with the first light-emitting element (6) or a light-emitting element provided separately from the first light-emitting element (6). When separately provided from the first light-emitting element (6), the second light-emitting element (3) is preferably provided to a peripheral frame (4) of a display screen (2), in the display screen (2), or as an accessory (5).

公开(公告)号：US20180351050A1

公开(公告)日：2018-12-06

申请号：US16044909

申请日：2018-07-25

Applicant: TOSHIBA MATERIALS CO., LTD. ,  TSUBOTA LABORATORY, INC.

Inventor： Masahiko Yamakawa ,  Hidemasa Torii ,  Toshihide Kurihara ,  Kazuo Tsubota

IPC: H01L33/50 ,  H01L25/075 ,  C09K11/77

CPC classification number: A61F9/00 ,  A61N5/06 ,  F21S2/00 ,  F21V9/30 ,  H01L33/50

Abstract: A light source for myopia prevention article includes a light emitter to emit light having an emission spectrum continuing from a first wavelength of not less than 360 nm nor more than 400 nm to a second wavelength of more than 400 nm.